Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Monsanto Co. -- Ignore unavailable to you. Want to Upgrade?

To: Anthony Wong who wrote (2098)	5/28/1999 5:07:00 PM
From: Dan Spillane	Read Replies (1) \| Respond to of 2539

Unsurprising. From what I gather, many (or all) of the NSAIDs interact with warfarin. The question is then whether COX-2s are safer than alternative NSAIDs in this respect -- unless there is some odd, unexpected paradoxical reaction. Although this might take some time to establish, from what I know about the mode of action of the COX-2s, it seems they might be LESS likely to interact with warfarin. This isn't just random talk; Anthony will recall the subject of platelets was discussed here and elsewhere many months ago, begun by a study he and I dug into, long before any of this was in the news. The bottom line seems to be patients on warfarin have few options when it comes to treatment of pain, without some risk. Also, 30 reports out of millions of prescriptions does not seem like a large number...and there were no deaths. Re: Monsanto Strengthens Precaution on Celebrex Use With Warfarin